On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Playing a Leadership Role in Point-of-Care Diagnostics Space

  • Avricore is a leader in the health diagnostics space offering the most sophisticated and complete solution for pharmacy today
  • The company is also leading a charge aimed at saving lives and money spent on health care
  • Avricore partnered with Abbott Diagnostics becoming the first third-party technology company to hold distribution agreements with the manufacturer
  • Avricore is currently entering a period of epic growth

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a health diagnostics technology innovator, is a leader in the point-of-care (“POC”) diagnostics space and a company of several firsts. Through its flagship platform and eponymous wholly owned subsidiary, HealthTab(TM), Avricore has provided a proactive approach in the fight against diseases such as prediabetes, diabetes, SARS-CoV-2 (COVID-19), Influenza A and B, strep, and RSV (https://nnw.fm/DwhZp).

Speaking during an interview with Stuart Smith as part of a recent Bell2Bell Podcast episode (https://nnw.fm/gtqW0), AVCR CEO Hector Bremner summed up the company’s unique diagnostics and cloud-based technology by saying, “We are really excited to be leaders in the field. There’s nobody quite like us. There are people that do parts of what we do, but we have brought the most sophisticated and most complete solution for pharmacy today.” 

Better known as HealthTab, the solution is a fully automated, turnkey POC testing system that combines high-quality analyzers from manufacturers such as Abbott Diagnostics and Abaxis Global Diagnostics with a cloud-based solution, creating a network that benefits pharmacies and patients alike. 

For patients, the HealthTab system, through the analyzers, tests multiple key biomarkers associated with chronic and infectious diseases and subsequently generates lab-accurate, real-time results that patients can view via the system’s consumer-facing interface. For pharmacies, Bremner noted, Avricore provides an additional revenue-generating opportunity in the form of cognitive pharmacy services.

In its vanguard role, Avricore is leading a charge that involves leveraging early detection and screening to save lives as well as the amount of money spent in health care. With early diagnosis having been proven as instrumental in reducing mortality and cardiovascular morbidity resulting from Type 2 diabetes (https://nnw.fm/vD18j), as well as death caused by COVID-19 (https://nnw.fm/N4ySI), HealthTab is indeed a boon.

“I’ve always really believed that we need a true health care system [in Canada] that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future. We’re really passionate about leading this charge,” continued Bremner.

Avricore’s leadoff stature also came into focus when it partnered with Abbott Diagnostics as part of a distribution agreement. Bremner, who described the partnership as groundbreaking, noted that Abbott does not ordinarily do distribution agreements for their technology with third-party technology companies like AVCR.

“Normally, to distribute Abbott technologies at this level, you have to be a fairly large distributor of health care technologies to begin with. We were extremely fortunate to pioneer this agreement and really break ground to see what was possible as a value-added reseller to bring our technology in combination with theirs,” observed Bremner.

Bremner noted that the partnership accelerated Avricore’s growth, further pointing out that the company is ideally poised for a great finish to the current year and continued growth through 2023, having repaid its debts and raised about $4.5 million this year.

Avricore is committed to becoming the world’s largest health diagnostics company. With a primary focus on developing a network of POC analyzers that utilize its HealthTab software in community pharmacy, the company is staking a claim as a leader in the space.

For more information, visit the company’s website at www.AvricoreHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://nnw.fm/AVCRF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217